# US 2017/0281597 A1 · Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281597 A1
- Document ID: US20170281597A1
- Status: Published application
- Kind: A1
- Application number: 15/629,678
- Filed: 2017-06-21
- Published: 2017-10-05
- Earliest claimed: 2002-03-20
- Assignees: Celgene Corporation
- Applicants: Celgene Corporation
- Inventors: George W. Muller; Peter H. Schafer; Hon-Wah Man; Chuansheng Ge
- Web page: https://patentgrep.com/patent/US20170281597A1

## CPC

- A61K 31/4035: Isoindoles, e.g. phthalimide
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/04: Antipruritics
- A61P 17/06: Antipsoriatics
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/24: Antidepressants
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/08: for leprosy
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/04: Immunostimulants
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 317/28: with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
- C07D 209/48: with oxygen atoms in positions 1 and 3, e.g. phthalimide
- C07B 2200/07: Optical isomers
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Stereomerically pure (+)-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (−) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-α or the inhibition of PDE4.

## Claims

### Claim at position 1

1-9. (canceled)

### Claim 10

A method of treating, preventing or managing bone loss, which comprises administering to a patient a therapeutically effective amount of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-4-acetylaminoisoindolin-1,3-dione:
or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 10)

The method of claim 10, wherein the bone loss is a primary bone loss.

### Claim 12 (depends on 11)

The method of claim 11, wherein the primary bone loss is primary type 1 osteoporosis.

### Claim 13 (depends on 11)

The method of claim 11, wherein the primary bone loss is primary type 2 osteoporosis.

### Claim 14 (depends on 10)

The method of claim 10, wherein the bone loss is secondary to other underlying disorders.

### Claim 15 (depends on 14)

The method of claim 14, wherein the underlying disorder is: an autoimmune disorder; a digestive or gastrointestinal disorder; a digestive or gastrointestinal disorder; a hematologic disorder; a neurological disorder; a mental illness; or cancer.

### Claim 16 (depends on 15)

The method of claim 15, wherein the autoimmune disorder is rheumatoid arthritis, lupus, multiple sclerosis or ankylosing spondylitis.

### Claim 17 (depends on 15)

The method of claim 15, wherein the digestive or gastrointestinal disorder is celiac disease or inflammatory bowel disease.

### Claim 18 (depends on 15)

The method of claim 15, wherein the digestive or gastrointestinal disorder is diabetes, hyperparathyroidism, hyperthyroidism, Cushing's syndrome, thyrotoxicosis, premature menopause, or unusual testosterone levels.

### Claim 19 (depends on 15)

The method claim 15, wherein the hematologic disorder is leukemia, lymphoma, multiple myeloma, sickle cell disease, a blood and bone marrow disorder or thalassemia.

### Claim 20 (depends on 15)

The method of claim 15, wherein the neurological disorder is stroke, Parkinson's disease, multiple sclerosis or spinal cord injury.

### Claim 21 (depends on 15)

The method of claim 15, wherein the mental illness is depression or an eating disorder.

### Claim 22 (depends on 15)

The method of claim 15, wherein the cancer is bone, breast or prostate cancer;

### Claim 23 (depends on 10)

The method of claim 10, wherein the bone loss is caused by a therapeutic agent.

### Claim 24 (depends on 23)

The method of claim 23, wherein the therapeutic agent is a corticosteroid, an antiepileptic, L-thyroxine, an aromatase inhibitor, methotrexate, depot-progesterone, a gonadotropin-releasing hormone agonist, a proton pump inhibitor, a thiazolidinedione, or lithium.

### Claim 25 (depends on 24)

The method of claim 24, wherein the corticosteroid is prednisone or dexamethasone.

### Claim 26 (depends on 24)

The method of claim 24, wherein the antiepileptic is a barbiturate or phenytoin.

### Claim 27 (depends on 10)

The method of claim 10, wherein the bone loss is osteogenesis imperfecta, osteomalacia, rickets, ostesis fibrosa cystic or Paget's disease.

### Claim 28 (depends on 10)

The method of claim 10, wherein the (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-4-acetylaminoisoindolin-1,3-dione or a pharmaceutically acceptable salt, is administered in combination or alternation with a therapeutically effective amount of one or more additional active agents.

### Claim 29 (depends on 28)

The method of claim 28, wherein the additional agent is a bisphosphonate, teriparatide, strontium renelate, raloxifene, denosumab, calcium, vitamin D, vitamin K or a combination thereof.
